ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
… Trial enrollment continuing for three clinical stage RNA therapies in development for inherited retinal diseases, … Board (SAB) with leaders in inherited retinal disease and RNA therapy. The SAB members are: James Shannon, MD, Chair of …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … Board (SAB) with leaders in inherited retinal disease and RNA therapy. In February, ProQR announced its participation …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … Phase 1b/2 trial results of the intravitreal sepofarsen RNA therapy in LCA10 (encore presentations) Full-field … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
… on track to be reported in H2 2020; Three clinical stage RNA therapies in development for inherited retinal diseases, … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber …
